“Get Help from Levi and Korsinsky if You’ve Lost Money: SMTC Under Active Investigation”

Levi & Korsinsky Investigates Semtech Corporation Charmingly Eccentric Semtech Corporation, a leading provider of high-performance analog and mixed-signal semiconductors, is currently under investigation for possible violations of federal securities laws. The company recently disclosed that its net sales of CopperEdge products are expected to fall below previous estimates for fiscal year 2026. This announcement has…

Read More

BioCardia’s 2024 Business Achievements and Financial Results: A Look Back

BioCardia’s 2024 Financial Results and Annual Report On March 26, 2025, BioCardia, Inc., a pioneering biotech company specializing in the development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, released its financial results for the year ended December 31, 2024. Simultaneously, the company filed its annual report on Form 10-K with the Securities…

Read More

Walmart Earnings Report: An In-Depth Analysis of the Impact of Tariffs on Profits

Walmart’s Fourth-Quarter Earnings: A Look at the Potential Impact of New Tariffs When Walmart, the world’s largest retailer, reports its fourth-quarter earnings results and guidance on Thursday, February 20, investors and analysts will be closely watching for any signs of the impact of new and potential tariffs. Walmart, like many other retailers, has been facing…

Read More

ModV Lawsuit Alert: Levi and Korsinsky Announce Class Action Against ModiVcare, Inc. (MODV)

Understanding Your Options after Suffering a Loss on ModivCare Inc. (MODV) Investment: A Comprehensive Guide Investing in the stock market comes with inherent risks, and even the most carefully chosen investments can result in losses. One such investment that has recently come under scrutiny is ModivCare Inc. (MODV), a healthcare technology company. If you’ve suffered…

Read More

Regenxbio Showcases RGX-121 at the 21st Annual World Symposium: Groundbreaking Gene Therapy Advancements

REGENXBIO’s MPS II Treatment Data to be Presented at WORLDSymposiumâ„¢ 2025 REGENXBIO Inc., a leading clinical-stage biotechnology company focused on developing and commercializing gene therapy products for patients with rare genetic diseases, recently made an exciting announcement. The company will be sharing data from its RGX-121 (clemidsogene lanparvovec) program for the treatment of Mucopolysaccharidosis type…

Read More